Shike Lou
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A machine learning-based predictive model for 48-week hepatitis B surface antigen seroclearance in chronic hepatitis B patients treated with pegylated interferon α-2b: prediction at week 24.
Journal: Frontiers in cell and developmental biology
Published: October 29, 2025
Difficulty in differentiating liver injury from an immune checkpoint inhibitor from chemotherapy.
Journal: Frontiers in pharmacology
Published: June 23, 2024
The expression landscape and clinical significance of methyltransferase-like 17 in human cancer and hepatocellular carcinoma: a pan-cancer analysis using multiple databases.
Journal: Cancer cell international
Published: January 23, 2024
The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB.
Journal: Frontiers in pharmacology
Published: February 12, 2023
The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China.
Journal: Frontiers in oncology
Published: November 28, 2022
A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN.
Journal: Antiviral research
Published: September 14, 2021
Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase.
Journal: Antiviral research
Published: August 04, 2020
Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.
Journal: Cancer medicine
Published: December 08, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026